Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Jan 29 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (1453)	10/6/2007 6:10:12 PM
From: ghmm	Read Replies (1) of 1494

rkrw, Didn't realize you follow NTII(D). I've looked at it and didn't really like the risk of the stroke drug but thought Xerecept and the Nemanda royalty were interesting and if the stock got low enough you could get Viprinex as a throw in. I didn't study the patent deeply but was surprised the Memantine royalty may be ending (I thought they'd have a couple more years). On the last call Paul seemed to imply it was up-in-the-air. Anyway with the recapitalization they are doing any interest I had disappeared. If I were a shareholder I would be extremely disappointed. The only thing I could think is Viprinex isn't looking too promising and no one would partner. I was curious if they are getting more patients in 4-6 hour range and thus had a higher hurdle to try to show efficacy.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next